NOVARTIS joins the Rare Disease Action Forum as member

    20 Feb, 2020

    In February 2020 Novartis joined the Rare Disease Action Forum (RDAF) as member. With its members coming from industry, patient organizations, Healthcare Professionals and research organizations, the RDAF acts as multi-stakeholder platform in the field of rare diseases. With its increased membership the RDAF reinforces its contribution to improve access to diagnosis, treatment and patient care for patients with rare diseases in Switzerland.

    Continue reading

    Joint statement on the KVV/OAMal and KLV/OPAS revision

    The RDAF co-signed a joint statement with other stakeholders on the revision of the Health Insurance Ordinance (KVV/OAMal) and Health Benefits Ordinance (KLV/OPAS). The statement highlights the potential negative impacts of the revision, including the following: -...